A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients

Transplant Proc. 1996 Apr;28(2):917-8.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antilymphocyte Serum / adverse effects
  • Antilymphocyte Serum / therapeutic use*
  • Diabetes Mellitus, Type 1 / surgery
  • Diabetic Nephropathies / surgery
  • Female
  • Follow-Up Studies
  • Graft Rejection / prevention & control
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Ketoconazole / therapeutic use
  • Kidney Transplantation / immunology
  • Kidney Transplantation / mortality
  • Male
  • Muromonab-CD3 / adverse effects
  • Muromonab-CD3 / therapeutic use*
  • Pancreas Transplantation / immunology*
  • Pancreas Transplantation / mortality
  • Prospective Studies
  • Pulmonary Edema / epidemiology
  • Respiratory Distress Syndrome / epidemiology
  • Survival Rate

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Ketoconazole